Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: A 1-year primate study on contraception and amenorrhea

Fertility and Sterility

Volumn 69, Issue 5, 1998, Pages 936-943

  Grow, Daniel R ^a   Reece, Margaret T ^b   Hsiu, Jeng G ^b   Adams, Lorrie ^b   Newcomb, Patricia M ^b   Williams, Robert F ^b   Hodgen, Gary D ^b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

Basic fibroblast growth factor; Endometrium; Mifepristone

Indexed keywords

ANTIGESTAGEN; MIFEPRISTONE;

AMENORRHEA; ANIMAL EXPERIMENT; ARTICLE; CONTRACEPTION; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM ATROPHY; MENSTRUATION; NONHUMAN; OVULATION; PRIORITY JOURNAL;

AMENORRHEA; ANIMALS; CONTRACEPTION; ENDOMETRIUM; FEMALE; FIBROBLAST GROWTH FACTOR 2; HORMONE ANTAGONISTS; LEUPROLIDE; MACACA FASCICULARIS; MIFEPRISTONE; OVULATION;

EID: 0032079856     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(98)00029-6     Document Type: Article

References (23)

1. 1. Spitz IM, Croxatto HB, Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol 1996; 36:47-81.
2. 2. Batista MC, Cartledge TP, Zellmer AW, Merino MJ, Axiotis C, Nieman LK. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy. Am J Obstet Gynecol 1992;167:60-5.
3. 3. Wolf JP, Hsiu JG, Anderson TL, Ulmann A, Baulieu EE, Hodgen GD. Noncompetitive antiestrogen effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril 1989;52: 1055-60.
4. 4. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992;327:1041-4.
5. 5. Van Uem JFHM, Hsiu JG, Chilik CF, Danforth DR, Ulmann A, Baulieu EE, et al. Contraceptive potential of RU 486 by ovulation inhibition: I. Pituitary versus ovarian action with the blockade of estrogen induced endometrial proliferation. Contraception 1989;40:171-84.
6. 6. Kettel ML, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SSC. Endocrine responses to long-term administration of the antiprogesterone RU 486 in patients with pelvic endometriosis. Fertil Steril 1991; 56:402-7.
7. 7. Murphy AA, Kettel LM, Morales A, Roberts VJ, Yen SSC. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513-7.
8. 8. Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a one-year primate study. J Clin Endocrinol Metab 1996;81:1933-9.
9. 9. Gospodarowicz D, Ferrara N, Schweigerer L, Nerfeld G. Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 1987;8:95-114.
10. 10. Presta M. Sex steroids modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. J Cell Physiol 1988;137:593-7.
11. 11. Irwin JC, Utian WH, Fikert RL. Sex steroids and growth factors differentially regulate the growth and differentiation of cultured human endometrial stromal cells. Endocrinology 1991;129:2385-92.
12. 12. Noyes RW, Hertig AW, Rock J. Dating the endometrial biopsy. Fertil Steril 1950;1:3.
13. 13. Frank ML, Poindexter AN, Cornin LM, Cox CA, Bateman L. One-year experience with subdermal contraceptive implants in the United States. Contraception 1993;48:229-43.
14. 14. Akhter H, Dunson TR, Ramesh NA, Begum K, Chowdhury T, Dighe N, et al. A five-year clinical evaluation of Norplant contraceptive subdermal implants in Bangladeshi acceptors. Contraception 1993;47:569-82.
15. 15. Diaz S, Croxatto HB, Pavez M, Belhadj H, Stern J, Sivin I. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception 1990;42:97-109.
16. 16. Slayden OD, Brenner RM. RU486 action after estrogen priming in the oviducts of rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab 1994;78:440-8.
17. 17. McDonnell DP, Goldman ME. RU 486 exerts antiestrogenic activities through a novel progesterone receptor: a form-mediated mechanism. J Biol Chem 1994;269:1145-9.
18. 18. Risau W. Vasculogenesis, angiogenesis and endothelial cell differentiation during embryonic development. In: Feinberg RN, Sherer GF, Auerbach R, editors. Issues in biomedicine: the development of the vascular system. Basel: Karger, 1991;58-68.
19. 19. Smith SK. Angiogenic growth factor expression in the uterus. Hum Reprod Update 1995;1:162-72.
20. 20. Neulen J, Williams RF, Hodgen GD. RU 486 (mifepristone): induction of dose-dependent elevations of estradiol receptor in endometrium from ovariectomized monkeys. J Clin Endocrinol Metab 1990;71:1074-5.
21. 21. Goodger AM, Rogers PA, Affandi B. Endometrial endothelial cell proliferation in long-term users of subdermal levonorgestrel. Hum Reprod 1994;9:1647-51.
22. 22. Rogers PA, Au CL, Affandi B. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod 1993;8:1396-404.
23. 23. Runic R, Schatz F, Krey L, Demopoulous R, Thung S, Wan L, et al. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-w contraception. J Clin Endocrinol Metab 1997;82:1983-8.